Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

FOXM1 targets NBS1 to regulate DNA damage-induced senescence and epirubicin resistance.

Khongkow P, Karunarathna U, Khongkow M, Gong C, Gomes AR, Yagüe E, Monteiro LJ, Kongsema M, Zona S, Man EP, Tsang JW, Coombes RC, Wu KJ, Khoo US, Medema RH, Freire R, Lam EW.

Oncogene. 2014 Aug 7;33(32):4144-55. doi: 10.1038/onc.2013.457. Epub 2013 Oct 21.

2.

The Forkhead Box M1 protein regulates BRIP1 expression and DNA damage repair in epirubicin treatment.

Monteiro LJ, Khongkow P, Kongsema M, Morris JR, Man C, Weekes D, Koo CY, Gomes AR, Pinto PH, Varghese V, Kenny LM, Charles Coombes R, Freire R, Medema RH, Lam EW.

Oncogene. 2013 Sep 26;32(39):4634-45. doi: 10.1038/onc.2012.491. Epub 2012 Oct 29.

3.

ATM and p53 regulate FOXM1 expression via E2F in breast cancer epirubicin treatment and resistance.

Millour J, de Olano N, Horimoto Y, Monteiro LJ, Langer JK, Aligue R, Hajji N, Lam EW.

Mol Cancer Ther. 2011 Jun;10(6):1046-58. doi: 10.1158/1535-7163.MCT-11-0024. Epub 2011 Apr 25.

4.

Paclitaxel targets FOXM1 to regulate KIF20A in mitotic catastrophe and breast cancer paclitaxel resistance.

Khongkow P, Gomes AR, Gong C, Man EP, Tsang JW, Zhao F, Monteiro LJ, Coombes RC, Medema RH, Khoo US, Lam EW.

Oncogene. 2016 Feb 25;35(8):990-1002. doi: 10.1038/onc.2015.152. Epub 2015 May 11.

5.

OTUB1 inhibits the ubiquitination and degradation of FOXM1 in breast cancer and epirubicin resistance.

Karunarathna U, Kongsema M, Zona S, Gong C, Cabrera E, Gomes AR, Man EP, Khongkow P, Tsang JW, Khoo US, Medema RH, Freire R, Lam EW.

Oncogene. 2016 Mar 17;35(11):1433-44. doi: 10.1038/onc.2015.208. Epub 2015 Jul 6.

6.

FOXM1 confers acquired cisplatin resistance in breast cancer cells.

Kwok JM, Peck B, Monteiro LJ, Schwenen HD, Millour J, Coombes RC, Myatt SS, Lam EW.

Mol Cancer Res. 2010 Jan;8(1):24-34. doi: 10.1158/1541-7786.MCR-09-0432. Epub 2010 Jan 12.

7.

The p38 MAPK-MK2 axis regulates E2F1 and FOXM1 expression after epirubicin treatment.

de Olano N, Koo CY, Monteiro LJ, Pinto PH, Gomes AR, Aligue R, Lam EW.

Mol Cancer Res. 2012 Sep;10(9):1189-202. Epub 2012 Jul 16.

8.

FOXM1 targets XIAP and Survivin to modulate breast cancer survival and chemoresistance.

Nestal de Moraes G, Delbue D, Silva KL, Robaina MC, Khongkow P, Gomes AR, Zona S, Crocamo S, Mencalha AL, Magalhães LM, Lam EW, Maia RC.

Cell Signal. 2015 Dec;27(12):2496-505. doi: 10.1016/j.cellsig.2015.09.013. Epub 2015 Sep 25.

PMID:
26404623
9.

RNF168 cooperates with RNF8 to mediate FOXM1 ubiquitination and degradation in breast cancer epirubicin treatment.

Kongsema M, Zona S, Karunarathna U, Cabrera E, Man EP, Yao S, Shibakawa A, Khoo US, Medema RH, Freire R, Lam EW.

Oncogenesis. 2016 Aug 15;5(8):e252. doi: 10.1038/oncsis.2016.57.

10.

SIRT6 modulates paclitaxel and epirubicin resistance and survival in breast cancer.

Khongkow M, Olmos Y, Gong C, Gomes AR, Monteiro LJ, Yagüe E, Cavaco TB, Khongkow P, Man EP, Laohasinnarong S, Koo CY, Harada-Shoji N, Tsang JW, Coombes RC, Schwer B, Khoo US, Lam EW.

Carcinogenesis. 2013 Jul;34(7):1476-86. doi: 10.1093/carcin/bgt098. Epub 2013 Mar 20.

PMID:
23514751
11.

Ataxia-telangiectasia-like disorder (ATLD)-its clinical presentation and molecular basis.

Taylor AM, Groom A, Byrd PJ.

DNA Repair (Amst). 2004 Aug-Sep;3(8-9):1219-25. Review.

PMID:
15279810
12.

Insights into a Critical Role of the FOXO3a-FOXM1 Axis in DNA Damage Response and Genotoxic Drug Resistance.

Nestal de Moraes G, Bella L, Zona S, Burton MJ, Lam EW.

Curr Drug Targets. 2016;17(2):164-77. Review.

13.

FoxM1c counteracts oxidative stress-induced senescence and stimulates Bmi-1 expression.

Li SK, Smith DK, Leung WY, Cheung AM, Lam EW, Dimri GP, Yao KM.

J Biol Chem. 2008 Jun 13;283(24):16545-53. doi: 10.1074/jbc.M709604200. Epub 2008 Apr 11.

14.

Productive replication of human papillomavirus 31 requires DNA repair factor Nbs1.

Anacker DC, Gautam D, Gillespie KA, Chappell WH, Moody CA.

J Virol. 2014 Aug;88(15):8528-44. doi: 10.1128/JVI.00517-14. Epub 2014 May 21.

15.

Defective Mre11-dependent activation of Chk2 by ataxia telangiectasia mutated in colorectal carcinoma cells in response to replication-dependent DNA double strand breaks.

Takemura H, Rao VA, Sordet O, Furuta T, Miao ZH, Meng L, Zhang H, Pommier Y.

J Biol Chem. 2006 Oct 13;281(41):30814-23. Epub 2006 Aug 10.

16.

ATM and the Mre11-Rad50-Nbs1 complex respond to nucleoside analogue-induced stalled replication forks and contribute to drug resistance.

Ewald B, Sampath D, Plunkett W.

Cancer Res. 2008 Oct 1;68(19):7947-55. doi: 10.1158/0008-5472.CAN-08-0971.

17.

Two-fold elevation of expression of FoxM1 transcription factor in mouse embryonic fibroblasts enhances cell cycle checkpoint activity by stimulating p21 and Chk1 transcription.

Tan Y, Chen Y, Yu L, Zhu H, Meng X, Huang X, Meng L, Ding M, Wang Z, Shan L.

Cell Prolif. 2010 Oct;43(5):494-504. doi: 10.1111/j.1365-2184.2010.00699.x.

PMID:
20887555
18.

FOXM1 is a transcriptional target of ERalpha and has a critical role in breast cancer endocrine sensitivity and resistance.

Millour J, Constantinidou D, Stavropoulou AV, Wilson MS, Myatt SS, Kwok JM, Sivanandan K, Coombes RC, Medema RH, Hartman J, Lykkesfeldt AE, Lam EW.

Oncogene. 2010 May 20;29(20):2983-95. doi: 10.1038/onc.2010.47. Epub 2010 Mar 8.

20.

L1CAM regulates DNA damage checkpoint response of glioblastoma stem cells through NBS1.

Cheng L, Wu Q, Huang Z, Guryanova OA, Huang Q, Shou W, Rich JN, Bao S.

EMBO J. 2011 Mar 2;30(5):800-13. doi: 10.1038/emboj.2011.10. Epub 2011 Feb 4.

Supplemental Content

Support Center